Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialReportar como inadecuado

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Osteoporosis International

, Volume 24, Issue 1, pp 227–235

First Online: 10 July 2012Received: 12 March 2012Accepted: 30 April 2012


SummaryIn a phase 2 study, continued denosumab treatment for up to 8 years was associated with continued gains in bone mineral density and persistent reductions in bone turnover markers. Denosumab treatment was well tolerated throughout the 8-year study.

IntroductionThe purpose of this study is to present the effects of 8 years of continued denosumab treatment on bone mineral density BMD and bone turnover markers BTM from a phase 2 study.

MethodsIn the 4-year parent study, postmenopausal women with low BMD were randomized to receive placebo, alendronate, or denosumab. After 2 years, subjects were reallocated to continue, discontinue, or discontinue and reinitiate denosumab; discontinue alendronate; or maintain placebo for two more years. The parent study was then extended for 4 years where all subjects received denosumab.

ResultsOf the 262 subjects who completed the parent study, 200 enrolled in the extension, and of these, 138 completed the extension. For the subjects who received 8 years of continued denosumab treatment, BMD at the lumbar spine N = 88 and total hip N = 87 increased by 16.5 and 6.8 %, respectively, compared with their parent study baseline, and by 5.7 and 1.8 %, respectively, compared with their extension study baseline. For the 12 subjects in the original placebo group, 4 years of denosumab resulted in BMD gains comparable with those observed during the 4 years of denosumab in the parent study. Reductions in BTM were sustained over the course of continued denosumab treatment. Reductions also were observed when the placebo group transitioned to denosumab. Adverse event profile was consistent with previous reports and an aging cohort.

ConclusionContinued denosumab treatment for 8 years was associated with progressive gains in BMD, persistent reductions in BTM, and was well tolerated.

KeywordsBone mineral density Bone turnover markers Denosumab Osteoporosis RANK ligand  Download fulltext PDF

Autor: M. R. McClung - E. M. Lewiecki - M. L. Geller - M. A. Bolognese - M. Peacock - R. L. Weinstein - B. Ding - E. Rockabr

Fuente: https://link.springer.com/

Documentos relacionados